Updating results

63 results

Sort: Relevance | Date

Pneumonia (community-acquired): antimicrobial prescribing (NG138)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Cellulitis and erysipelas: antimicrobial prescribing (NG141)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Diabetic foot problems: prevention and management (NG19)

This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

NICE guideline Published August 2015 Last updated October 2019

Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of hospital-acquired pneumonia. It does not cover ventilator-associated pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Endocuff Vision for assisting visualisation during colonoscopy (MTG45)

Evidence-based decisions on Endocuff Vision for assisting visualisation during colonoscopy

Medical technologies guidance Published June 2019

Curos for preventing infections when using needleless connectors (MTG44)

Evidence-based recommendations on Curos for preventing infections when using needleless connectors

Medical technologies guidance Published May 2019

PICO negative pressure wound dressings for closed surgical incisions (MTG43)

Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions

Medical technologies guidance Published May 2019 Last updated August 2019

The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (MTG24)

Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters

Medical technologies guidance Published March 2015 Last updated May 2019

EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

Evidence-based recommendations on the EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing

Medical technologies guidance Published January 2013 Last updated October 2019

Ambu aScope4 Broncho for use in unexpected difficult airways (MTG14)

Evidence-based recommendations on the Ambu aScope4 Broncho for use in unexpected difficult airways

Medical technologies guidance Published July 2013 Last updated June 2019

The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites (MTG25)

Evidence-based recommendations on the 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites

Medical technologies guidance Published July 2015 Last updated September 2019

Implant insertion for prominent ears (IPG660)

Evidence-based recommendations on implant insertion for prominent ears in children, young people and adults

Interventional procedures guidance Published September 2019

Bioprosthetic plug insertion for anal fistula (IPG662)

Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults

Interventional procedures guidance Published September 2019

High-intensity focused ultrasound for glaucoma (IPG661)

Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults

Interventional procedures guidance Published September 2019

Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults

Interventional procedures guidance Published August 2019

Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids (IPG657)

Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults

Interventional procedures guidance Published July 2019

Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)

Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults

Interventional procedures guidance Published July 2019

Cardiac contractility modulation device implantation for heart failure (IPG655)

Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults

Interventional procedures guidance Published June 2019

Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia (IPG654)

Evidence-based recommendations on reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia

Interventional procedures guidance Published June 2019

Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults

Interventional procedures guidance Published June 2019

Bronchoscopic thermal vapour ablation for upper-lobe emphysema (IPG652)

Evidence-based recommendations on bronchoscopic thermal vapour ablation for upper-lobe emphysema in adults

Interventional procedures guidance Published June 2019

Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (IPG651)

Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg in adults

Interventional procedures guidance Published June 2019

Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI (IPG650)

Evidence-based recommendations on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI (transcatheter aortic valve

Interventional procedures guidance Published June 2019

Therapeutic hypothermia for acute ischaemic stroke (IPG647)

Evidence-based recommendations on therapeutic hypothermia (using a cooling device to reduce the body’s temperature) for acute ischaemic stroke in adults

Interventional procedures guidance Published May 2019

Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG649)

Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults

Interventional procedures guidance Published May 2019

Collagen paste for closing an anal fistula (IPG648)

Evidence-based recommendations on collagen paste for closing an anal fistula in adults

Interventional procedures guidance Published May 2019

Midcarpal hemiarthroplasty for wrist arthritis (IPG663)

Evidence-based recommendations on midcarpal hemiarthroplasty (using a metal implant to create an artificial wrist joint) for wrist arthritis in adults

Interventional procedures guidance Published October 2019

Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer (IPG659)

Evidence-based recommendations on low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer in adults

Interventional procedures guidance Published August 2019

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Technology appraisal guidance Published September 2019

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Technology appraisal guidance Published September 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Technology appraisal guidance Published May 2019

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults

Technology appraisal guidance Published April 2019

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Technology appraisal guidance Published June 2019

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous NSCLC

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Technology appraisal guidance Published June 2019

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults

Technology appraisal guidance Published June 2019

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Technology appraisal guidance Published May 2019

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

Technology appraisal guidance Published May 2019

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults

Technology appraisal guidance Published May 2019

Bisphosphonates for treating osteoporosis (TA464)

Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults

Technology appraisal guidance Published August 2017 Last updated July 2019

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance Published September 2014 Last updated June 2019

Nusinersen for treating spinal muscular atrophy (TA588)

Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults

Technology appraisal guidance Published July 2019

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Evidence-based recommendations on dacomitinib (Vizimpro) for locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published August 2019

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults

Technology appraisal guidance Published August 2019

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) in adults

Technology appraisal guidance Published August 2019

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019